Abstract ND11: AZD0022: a potent, oral KRASG12D-selective inhibitor that drives robust pathway inhibition and anti-tumour activity in KRASG12D models
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Carla P. Martins, Alex Koers, Sreyoshi Mitra, Alison Peter, Katie Young, Christopher Chambers, Zoe Underwood, Kevin Beaumont, Sofia Guzzetti, Christopher Stubbs, Derek Barratt, Benjamin Phillips, Eleanor Wigmore, Melissa Chapman, Michele Moschetta, Simon Barry, Susan Critchlow, Michael Niedbala
Institutions: AstraZeneca (United Kingdom), AstraZeneca (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4410596084